ReviewMolecular cancer2025
Bispecific antibodies and nanotechnology: a strategic alliance in cancer immunotherapy.
Review in Molecular cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Biomolecular Interfaces in Targeted Nano-Drug Delivery: Molecular Recognition, Signaling Modulation, and Translational Pathways.Biomolecules · 2026Review
- Advances in ligand-targeted nanodelivery systems for leukemia therapy: from single- to dual-ligand strategies.Journal of translational medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Bispecific antibodies (bsAbs), designed to recognize two distinct antigens or epitopes, enable innovative mechanisms of action for emerging generations of cancer immunotherapies. Despite their potential, bsAb therapeutics face several challenges related to their biodistribution and pharmacokinetics, which often result in a suboptimal efficacy/toxicity balance. Starting with a brief description of the relevance of bsAbs in cancer immunotherapy, this review aims to critically analyze the synergistic potential of nanotechnology and bsAb technology oriented to enhance therapeutic efficiency while reducing toxicity. This synergy can be achieved through several strategies: (i) bsAbs may function as targeting ligands to improve the biodistribution of drug-loaded nanocarriers; (ii) therapeutic bsAbs incorporated into nanocarriers may easily overcome biological barriers and reach their target; and (iii) bsAbs can be generated in vivo using mRNA-loaded nanocarriers encoding them. This review addresses challenges in these emerging areas and provides insights into future directions for this promising field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.